Treatment, thrombosis, and bleeding in patients with splenic infarcts
• A new thrombotic risk found in 23% of patients, mainly AF and malignancy • Cryptogenic splenic infarction is rare • Most patients (58%) were discharged with any antithrombotic therapy. • Recurrent thrombosis at 1 year was high (19.6%), mainly arterial. • Major bleeding was also high (10%) and 1-year mortality was 50%
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Tel Aviv University (IL)
- Cornell University (US)
- Rabin Medical Center (IL)
- Meir Medical Center (IL)
Publication Details
- Journal
- Thrombosis Update
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1016/j.tru.2025.100230
- Primary Topic
- Abdominal Trauma and Injuries
- Type
- article
- Field-Weighted Citation Impact
- 0.00